REGEN BIOPHARMA, INC.: 10-K filed 2021-06-21
What REGEN BIOPHARMA, INC. reported in its annual report filed 2021-06-21 (fiscal FY 2019): 28 published measures, 69 facts as tagged in accession 0001607062-21-000165.
This filing
- Form
- 10-K (annual report)
- Filed
- 2021-06-21
- Fiscal period
- fiscal FY 2019
- Accession
- 0001607062-21-000165 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 99,087 | USD | |
| At 2018-09-30 | 209,018 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 11,007,882 | USD | |
| At 2018-09-30 | 9,330,689 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -10,908,795 | USD | |
| At 2019-06-30 | -12,792,604 | USD | |
| At 2019-03-31 | -8,820,991 | USD | |
| At 2018-12-31 | -8,661,761 | USD | |
| At 2018-09-30 | -9,121,671 | USD | |
| At 2018-06-30 | -8,567,198 | USD | |
| At 2018-03-31 | -8,546,711 | USD | |
| At 2017-12-31 | -7,800,232 | USD | |
| At 2017-09-30 | -5,251,335 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 7,855 | USD | |
| At 2018-09-30 | 8,018 | USD | |
| At 2017-09-30 | 269,973 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | -2,623,176 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -4,715,200 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | -481,793 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -1,577,836 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 110,000 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 100,000 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 431,771 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 1,321,622 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 49,858 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -5,741 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -19,998,086 | USD | |
| At 2018-09-30 | -17,457,044 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 2,071,155,682 | shares | 365 |
| 2017-10-01 to 2018-09-30 | 152,091,330 | shares | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | -756,785 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -1,425,783 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 79,117 | USD | |
| At 2018-09-30 | 42,771 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 295,167 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 259,069 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 11,002,904 | USD | |
| At 2018-09-30 | 8,673,511 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 92,000 | USD | |
| At 2018-09-30 | 80,567 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 71,186 | USD | |
| At 2018-09-30 | 0 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 45,605 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 374,436 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 600,001,406 | shares | |
| At 2018-09-30 | 180,315,107 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 8,261,993 | USD | |
| At 2018-09-30 | 7,517,888 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 0 | USD | |
| At 2018-09-30 | 52,948 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -10,908,795 | USD | |
| At 2018-09-30 | -9,121,671 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 0 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 1,870,027 | USD | 92 |
| 2019-04-01 to 2019-06-30 | -4,405,083 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -333,177 | USD | 90 |
| 2018-10-01 to 2018-12-31 | 245,057 | USD | 92 |
| 2018-07-01 to 2018-09-30 | -981,602 | USD | 92 |
| 2018-04-01 to 2018-06-30 | -107,596 | USD | 91 |
| 2018-01-01 to 2018-03-31 | -840,851 | USD | 90 |
| 2017-10-01 to 2017-12-31 | -2,785,149 | USD | 92 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | -2,623,176 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -4,715,200 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 500,640 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 743,755 | USD | 365 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 71,186 | USD | 365 |
| 2017-10-01 to 2018-09-30 | 0 | USD | 365 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-09-30 | 11,429 | USD | 365 |
| 2017-10-01 to 2018-09-30 | -415,190 | USD | 365 |
Inspect the source
- Entity
- REGEN BIOPHARMA, INC. / CIK 0001589150
- Captured
- 2026-09-20T09:23:48.532Z
- SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))